Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial.

EORTC QLQ-C30 HR+/HER2− Sacituzumab govitecan antibody–drug conjugate metastatic breast cancer phase III quality of life

Journal

The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837

Informations de publication

Date de publication:
15 May 2024
Historique:
received: 23 02 2024
accepted: 06 04 2024
medline: 15 5 2024
pubmed: 15 5 2024
entrez: 15 5 2024
Statut: aheadofprint

Résumé

The TROPiCS-02 study (NCT03901339) demonstrated that sacituzumab govitecan (SG) has superior clinical outcomes over treatment of physician's choice (TPC) chemotherapy in patients with hormone receptor-positive, human epidermal growth factor 2 receptor-negative (HR+/HER2-) metastatic breast cancer (mBC). Here, we present health-related quality of life (HRQoL) patient-reported outcome (PRO) findings from this study. Eligible adults with HR+/HER2- mBC who previously received a taxane, endocrine-based therapy, a CDK4/6 inhibitor, and 2-4 lines of chemotherapy were randomized 1:1 to receive SG or TPC until progression or unacceptable toxicity. PROs were assessed at baseline and on day 1 of each cycle, using the European Organization for Research and Treatment of Cancer Quality-of-Life Core 30 (EORTC QLQ-C30), EQ-5D-5L, and PRO Common Terminology Criteria for Adverse Events (PRO-CTCAE). Compared to TPC, overall least square mean change from baseline was significantly better for SG for physical functioning and dyspnea, but worse for diarrhea. Time to first clinically meaningful worsening or death was significantly longer for SG in global health status/quality of life, physical functioning, fatigue, emotional functioning, dyspnea, insomnia, and financial difficulties of the EORTC QLQ-C30 and the EQ-VAS, but longer for TPC in diarrhea. Few patients in both arms reported experiencing any worsening to level 3 or 4 treatment-related symptomatic events during treatment, as assessed by 16 PRO-CTCAE items, except for diarrhea frequency and amount of hair loss, which favored TPC. SG was associated with an HRQoL benefit in most symptoms and functioning, compared with TPC. This supports the favorable profile of SG as a treatment option for patients with pretreated HR+/HER2- mBC.

Sections du résumé

BACKGROUND BACKGROUND
The TROPiCS-02 study (NCT03901339) demonstrated that sacituzumab govitecan (SG) has superior clinical outcomes over treatment of physician's choice (TPC) chemotherapy in patients with hormone receptor-positive, human epidermal growth factor 2 receptor-negative (HR+/HER2-) metastatic breast cancer (mBC). Here, we present health-related quality of life (HRQoL) patient-reported outcome (PRO) findings from this study.
PATIENTS AND METHODS METHODS
Eligible adults with HR+/HER2- mBC who previously received a taxane, endocrine-based therapy, a CDK4/6 inhibitor, and 2-4 lines of chemotherapy were randomized 1:1 to receive SG or TPC until progression or unacceptable toxicity. PROs were assessed at baseline and on day 1 of each cycle, using the European Organization for Research and Treatment of Cancer Quality-of-Life Core 30 (EORTC QLQ-C30), EQ-5D-5L, and PRO Common Terminology Criteria for Adverse Events (PRO-CTCAE).
RESULTS RESULTS
Compared to TPC, overall least square mean change from baseline was significantly better for SG for physical functioning and dyspnea, but worse for diarrhea. Time to first clinically meaningful worsening or death was significantly longer for SG in global health status/quality of life, physical functioning, fatigue, emotional functioning, dyspnea, insomnia, and financial difficulties of the EORTC QLQ-C30 and the EQ-VAS, but longer for TPC in diarrhea. Few patients in both arms reported experiencing any worsening to level 3 or 4 treatment-related symptomatic events during treatment, as assessed by 16 PRO-CTCAE items, except for diarrhea frequency and amount of hair loss, which favored TPC.
CONCLUSIONS CONCLUSIONS
SG was associated with an HRQoL benefit in most symptoms and functioning, compared with TPC. This supports the favorable profile of SG as a treatment option for patients with pretreated HR+/HER2- mBC.

Identifiants

pubmed: 38748596
pii: 7674171
doi: 10.1093/oncolo/oyae088
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Gilead Sciences

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press.

Auteurs

Hope S Rugo (HS)

Department of Medicine, University of California-San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, United States.

Peter Schmid (P)

Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.

Sara M Tolaney (SM)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.

Florence Dalenc (F)

Institut Claudius Régaud, Toulouse, France.

Frederik Marmé (F)

Medical Faculty Mannheim, Heidelberg University, University Hospital Mannheim, Heidelberg, Germany.

Ling Shi (L)

Department of Evidence Synthesis, Modeling and Communication, Evidera Inc., Bethesda, MD, United States.

Wendy Verret (W)

Department of Clinical Development, Gilead Sciences, Inc., Foster City, CA, United States.

Anuj Shah (A)

Department of Health Economics and Outcomes Research, Gilead Sciences, Inc., Foster City, CA, United States.

Mahdi Gharaibeh (M)

Department of Health Economics and Outcomes Research, Gilead Sciences, Inc., Foster City, CA, United States.

Aditya Bardia (A)

Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, United States.

Javier Cortes (J)

Oncology Department, International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain.
Medica Scientia Innovation Research (MedSIR), Barcelona, Spain.
Faculty of Biomedical and Health Sciences, Department of Medicine, Universidad Europea de Madrid, Madrid, Spain.

Classifications MeSH